通过生物信息学分析探索2型糖尿病诱导的阿尔茨海默病的分子标
Lin Gao1, Chengyu Huang1, Hui Li1
1The Graduate School, Xuzhou Medical University, Xuzhou, Jiangsu, 221004, China.
Epigenomics
|August 9, 2023
概括
2型糖尿病 (T2DM) 可能通过CD44和STAT3.3的相互作用诱导阿尔茨海默病 (AD). 这项研究确定了这些关键基因,为T2DM相关的AD提供了潜在的新治疗点.
科学领域:
- 生物医学研究的研究.
- 基因组学就是基因组学.
- 计算生物学是一种计算生物学.
背景情况:
- 2型糖尿病 (T2DM) 是一个日益严重的全球健康问题.
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病.
- 新出现的证据表明T2DM与AD风险增加之间存在联系.
研究的目的:
- 调查T2DM诱导的AD背后的分子机制.
- 为了确定T2DM和AD之间共享的差异表达基因.
- 发现T2DM相关AD的潜在治疗点.
主要方法:
- 权重基因联合表达网络分析 (WGCNA) 用于识别基因模块.
- 差异基因表达分析以找到显著的基因重叠.
- 分子对接模拟用于预测蛋白质-蛋白质相互作用.
主要成果:
- 确定了T2DM和AD共同的显著差异表达的基因.
- 作为一个关键因素,CD44和STAT3之间的直接相互作用被强调.
- CD44和STAT3被确定为T2DM-AD途径中的枢纽基因.
结论:
- CD44-STAT3相互作用是T2DM诱导的AD的一个潜在机制.
- 像CD44和STAT3这样的枢纽基因提供了新的治疗点.
- 这项研究提供了一种基于生物信息学的新方法来治疗T2DM相关的AD.
相关概念视频
01:26Alzheimer's Disease: Overview
521
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
521
01:22Alzheimer's Disease: Treatment
215
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
215